Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review

Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials

(2020) M. Chalabi et al.   ANNALS OF ONCOLOGY

Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis

(2020) Leitao Sun et al.   Scientific Reports

Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.

(2020) Charles S. Fuchs et al.   JOURNAL OF CLINICAL ONCOLOGY

The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy

(2020) Xueping Wang et al.   Molecular Cancer

Sex-associated molecular differences for cancer immunotherapy

(2020) Youqiong Ye et al.   Nature Communications

Cytokines regulate the antigen-presenting characteristics of human circulating and tissue-resident intestinal ILCs

(2020) Anna Rao et al.   Nature Communications

Cell Intrinsic and Systemic Metabolism in Tumor Immunity and Immunotherapy

(2020) Michael F. Coleman et al.   Cancers

Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer

(2019) Akinori Sasaki et al.   Gastric Cancer

PTEN Mutations Trigger Resistance to Immunotherapy

(2019) Feixiong Cheng et al.   TRENDS IN MOLECULAR MEDICINE

PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua

(2019) Paola Vacca et al.   Mucosal Immunology

Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD‐1 receptor

(2019) Nicola Tumino et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy

(2019) Marilina García-Aranda et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors.

(2019) Kyriakos P. Papadopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of cholesterolemia and body mass index on outcome of metastatic non small cell lung cancer treated with immunotherapy.

(2019) Giulia Galli et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination of Osimertinib with Durvalumab in Epidermal Growth Factor Receptor–Mutant Non–Small Cell Lung Cancer: Is There Room for Reinvestigation?

(2019) Myung-Ju Ahn   Journal of Thoracic Oncology

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment

(2019) Ming Yi et al.   Molecular Cancer

Helper-like innate lymphoid cells and cancer immunotherapy

(2019) Adeline Crinier et al.   SEMINARS IN IMMUNOLOGY

Physical Activity Plus Energy Restriction Prevents 4T1.2 Mammary Tumor Progression, MDSC Accumulation, and an Immunosuppressive Tumor Microenvironment

(2019) William J. Turbitt et al.   Cancer Prevention Research

First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1

(2019) Neeta Somaiah et al.   CLINICAL CANCER RESEARCH

Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients

(2019) Shin Hye Yoo et al.   Scientific Reports

Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors

(2019) Andy S. Ding et al.   Frontiers in Immunology

Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions

(2019) Francesca Romana Mariotti et al.   Frontiers in Immunology

Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases

(2019) Chuan Huang et al.   JOURNAL OF AUTOIMMUNITY

Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy

(2019) Shixiang Wang et al.   MOLECULES

PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition

(2019) Yilun Wu et al.   Frontiers in Immunology

A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice

(2019) Sarah Lévesque et al.   OncoImmunology

The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients

(2019) Douglas Donnelly et al.   Journal for ImmunoTherapy of Cancer

VISTA is an acidic pH-selective ligand for PSGL-1

(2019) Robert J. Johnston et al.   NATURE

Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies

(2019) Spencer C. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor

(2019) Xianguang Bai et al.   OncoTargets and Therapy

Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma

(2019) Jonathan A. Trujillo et al.   Journal for ImmunoTherapy of Cancer

Harnessing tumor-associated macrophages as aids for cancer immunotherapy

(2019) Xiaolei Li et al.   Molecular Cancer

WNT Signaling in Tumors: The Way to Evade Drugs and Immunity

(2019) Elena Martin-Orozco et al.   Frontiers in Immunology

T-Regulatory Cells In Tumor Progression And Therapy

(2019) Amit Verma et al.   Cancer Management and Research

Regulatory T cells: a potential target in cancer immunotherapy

(2018) Kohei Shitara et al.   Annals of the New York Academy of Sciences

Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC

(2018) Xue Li et al.   CANCER LETTERS

Do immune checkpoint inhibitors perform identically in patients with weight extremes?

(2018) Elie El Rassy et al.   Immunotherapy

Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)

(2018) Yingcheng Wu et al.   INTERNATIONAL JOURNAL OF CANCER

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

(2018) Hira Rizvi et al.   JOURNAL OF CLINICAL ONCOLOGY

Frontline Science: High fat diet and leptin promote tumor progression by inducing myeloid-derived suppressor cells

(2018) Virginia K. Clements et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Nivolumab Plus Erlotinib in Patients With EGFR -Mutant Advanced NSCLC

(2018) Scott Gettinger et al.   Journal of Thoracic Oncology

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

(2018) Fabio Conforti et al.   LANCET ONCOLOGY

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

(2018) Robert L. Ferris et al.   ORAL ONCOLOGY

The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

(2018) Vyara Matson et al.   SCIENCE

Next generation immune-checkpoints for cancer therapy

(2018) Chiara Donini et al.   Journal of Thoracic Disease

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

(2018) Rebekka Weber et al.   Frontiers in Immunology

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer

(2018) Magalie Dosset et al.   OncoImmunology

Synopsis of arachidonic acid metabolism: A review

(2018) Violette Said Hanna et al.   Journal of Advanced Research

Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.

(2018) Eiji Shinozaki et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).

(2018) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

PPAR-induced fatty acid oxidation in T cells increases the number of tumor-reactive CD8+ T cells and facilitates anti-PD-1 therapy

(2018) Partha S. Chowdhury et al.   Cancer Immunology Research

Interferon gamma in cancer immunotherapy

(2018) Ling Ni et al.   Cancer Medicine

Not All Immune Checkpoints Are Created Equal

(2018) Annika De Sousa Linhares et al.   Frontiers in Immunology

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

(2018) Roberto Ferrara et al.   JAMA Oncology

Cytokines in clinical cancer immunotherapy

(2018) Pedro Berraondo et al.   BRITISH JOURNAL OF CANCER

Hyperprogressive disease: recognizing a novel pattern to improve patient management

(2018) Stéphane Champiat et al.   Nature Reviews Clinical Oncology

Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 Agonist

(2018) Fanny Polesso et al.   Cancer Immunology Research

Antigenic Peptide Prediction From E6 and E7 Oncoproteins of HPV Types 16 and 18 for Therapeutic Vaccine Design Using Immunoinformatics and MD Simulation Analysis

(2018) Basit Jabbar et al.   Frontiers in Immunology

Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials

(2018) Antonino Grassadonia et al.   Journal of Clinical Medicine

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors

(2017) Frederick Arce Vargas et al.   IMMUNITY

Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity

(2017) Ryu Watanabe et al.   JOURNAL OF CLINICAL INVESTIGATION

PD-1 regulates KLRG1+group 2 innate lymphoid cells

(2017) Samuel Taylor et al.   JOURNAL OF EXPERIMENTAL MEDICINE

OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057

(2017) Solange Peters et al.   Journal of Thoracic Oncology

An immunogenic personal neoantigen vaccine for patients with melanoma

(2017) Patrick A. Ott et al.   NATURE

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

(2017) Alice O. Kamphorst et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Emerging targets in cancer immunotherapy

(2017) Samantha Burugu et al.   SEMINARS IN CANCER BIOLOGY

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

(2017) Moshe Sade-Feldman et al.   Nature Communications

DNA Damage and Repair Biomarkers of Immunotherapy Response

(2017) Kent W. Mouw et al.   Cancer Discovery

Prostaglandin E2 and PD-1 mediated inhibition of antitumor CTL responses in the human tumor microenvironment

(2017) Jie Miao et al.   Oncotarget

Acute Dietary Restriction Acts via TOR, PP2A, and Myc Signaling to Boost Innate Immunity in Drosophila

(2017) Jung-Eun Lee et al.   Cell Reports

The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy

(2017) Daniel Zingg et al.   Cell Reports

Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis

(2017) Rajeev K. Shrimali et al.   Cancer Immunology Research

PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells

(2017) Carmen Stecher et al.   Frontiers in Immunology

Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors

(2017) Eva M. Palsson-McDermott et al.   Frontiers in Immunology

Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients

(2017) Arthur E. Frankel et al.   NEOPLASIA

NSAIDs Use and Reduced Metastasis in Cancer Patients: results from a meta-analysis

(2017) Xiaoping Zhao et al.   Scientific Reports

CTLA-4 and PD-1 Pathways

(2016) Elizabeth I. Buchbinder et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Tumor antigens in human cancer control

(2016) Sander Kelderman et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity

(2016) Stefano Di Biase et al.   CANCER CELL

Microbiome and Anticancer Immunosurveillance

(2016) Laurence Zitvogel et al.   CELL

Caloric Restriction Leads to Browning of White Adipose Tissue through Type 2 Immune Signaling

(2016) Salvatore Fabbiano et al.   Cell Metabolism

Regulatory T cells in cancer immunotherapy

(2016) Atsushi Tanaka et al.   CELL RESEARCH

Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

(2016) Z. Ma et al.   CLINICAL CANCER RESEARCH

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

(2016) Stéphane Champiat et al.   CLINICAL CANCER RESEARCH

Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab

(2016) Jon Bjoern et al.   CYTOTHERAPY

Rationale for anti-GITR cancer immunotherapy

(2016) Deborah A. Knee et al.   EUROPEAN JOURNAL OF CANCER

Rationale for anti-OX40 cancer immunotherapy

(2016) Sandrine Aspeslagh et al.   EUROPEAN JOURNAL OF CANCER

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

(2016) Jonathan M. Pitt et al.   IMMUNITY

The role of neoantigens in response to immune checkpoint blockade

(2016) Nadeem Riaz et al.   INTERNATIONAL IMMUNOLOGY

Hypoxia-inducible factors: a central link between inflammation and cancer

(2016) Daniel Triner et al.   JOURNAL OF CLINICAL INVESTIGATION

Dietary restriction improves repopulation but impairs lymphoid differentiation capacity of hematopoietic stem cells in early aging

(2016) Duozhuang Tang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

(2016) Scott J Antonia et al.   LANCET ONCOLOGY

Single-cell RNA-seq identifies a PD-1hi ILC progenitor and defines its development pathway

(2016) Yong Yu et al.   NATURE

Targeting EZH2 in cancer

(2016) Kimberly H Kim et al.   NATURE MEDICINE

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Wnt signaling in cancer

(2016) T Zhan et al.   ONCOGENE

Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma

(2016) Stefani Spranger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Obesity Paradox in Cancer: a Review

(2016) Hannah Lennon et al.   Current Oncology Reports

PKM2 and cancer: The function of PKM2 beyond glycolysis

(2016) GAOCHAO DONG et al.   Oncology Letters

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

(2016) Valsamo Anagnostou et al.   Cancer Discovery

The concept of immune surveillance against tumors: The first theories

(2016) Domenico Ribatti   Oncotarget

Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups

(2016) G. de Velasco et al.   Cancer Immunology Research

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

(2015) Chih-Hao Chang et al.   CELL

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

(2015) Katherine B. Chiappinelli et al.   CELL

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

(2015) Santiago Zelenay et al.   CELL

Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer

(2015) E. K. Moon et al.   CLINICAL CANCER RESEARCH

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

(2015) L. Liu et al.   CLINICAL CANCER RESEARCH

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

(2015) S. Loi et al.   CLINICAL CANCER RESEARCH

Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma

(2015) Cheng Lin et al.   Clinical Lung Cancer

Proton pump inhibitors alter the composition of the gut microbiota

(2015) Matthew A Jackson et al.   GUT

Metabolic Reprogramming of Immune Cells in Cancer Progression

(2015) Subhra K. Biswas   IMMUNITY

TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients

(2015) Joe-Marc Chauvin et al.   JOURNAL OF CLINICAL INVESTIGATION

VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors

(2015) Thibault Voron et al.   JOURNAL OF EXPERIMENTAL MEDICINE

High Mitochondrial Respiration and Glycolytic Capacity Represent a Metabolic Phenotype of Human Tolerogenic Dendritic Cells

(2015) Frano Malinarich et al.   JOURNAL OF IMMUNOLOGY

Differential impact of obesity and diabetes mellitus on survival after liver resection for colorectal cancer metastases

(2015) Sousana Amptoulach et al.   JOURNAL OF SURGICAL RESEARCH

Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy

(2015) Andrew B Sharabi et al.   LANCET ONCOLOGY

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

(2015) Dongjun Peng et al.   NATURE

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1

(2015) E. Vacchelli et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma

(2015) Siwen Hu-Lieskovan et al.   Science Translational Medicine

Immunological mechanisms of the antitumor effects of supplemental oxygenation

(2015) Stephen M. Hatfield et al.   Science Translational Medicine

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

(2015) W. Peng et al.   Cancer Discovery

The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies

(2015) Leisha A. Emens et al.   Cancer Immunology Research

Tryptophan-Degrading Enzymes in Tumoral Immune Resistance

(2015) Nicolas van Baren et al.   Frontiers in Immunology

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties

(2015) Cara L Haymaker et al.   OncoImmunology

New and emerging factors in tumorigenesis: an overview

(2015) Suwon Kim   Cancer Management and Research

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal

(2015) Stefanie N. Linch et al.   Frontiers in Oncology

PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma

(2015) Wei-Ren Liu et al.   Oncotarget

Pathways to Tumorigenesis—Modeling Mutation Acquisition in Stem Cells and Their Progeny

(2015) Rina Ashkenazi et al.   NEOPLASIA

Postdiagnosis body mass index and risk of mortality in colorectal cancer survivors: a prospective study and meta-analysis

(2014) Sabrina Schlesinger et al.   CANCER CAUSES & CONTROL

The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function

(2014) Robert J. Johnston et al.   CANCER CELL

Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging

(2014) Michelle Farazi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

VISTA Is an Immune Checkpoint Molecule for Human T Cells

(2014) J. L. Lines et al.   CANCER RESEARCH

VISTA Regulates the Development of Protective Antitumor Immunity

(2014) I. Le Mercier et al.   CANCER RESEARCH

CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models

(2014) Y. Zhu et al.   CANCER RESEARCH

Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

(2014) T. Chodon et al.   CLINICAL CANCER RESEARCH

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

(2014) P. F. Robbins et al.   CLINICAL CANCER RESEARCH

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?

(2014) S. Nag et al.   CURRENT MEDICINAL CHEMISTRY

New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape

(2014) Deepak Mittal et al.   CURRENT OPINION IN IMMUNOLOGY

Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses

(2014) Nicole Joller et al.   IMMUNITY

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

(2014) Xiaozhou Fan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

(2014) Muhammad Zaeem Noman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs

(2014) Lei Lu et al.   Journal of Translational Medicine

Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts

(2014) Pragya Srivastava et al.   LEUKEMIA RESEARCH

Inducible costimulator facilitates T-dependent B cell activation by augmenting IL-4 translation

(2014) Mathieu Gigoux et al.   MOLECULAR IMMUNOLOGY

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

(2014) Gregory T Motz et al.   NATURE MEDICINE

Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma

(2014) John C. Morris et al.   PLoS One

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

(2014) S. L. Highfill et al.   Science Translational Medicine

Immune checkpoint receptors in regulating immune reactivity in rheumatic disease

(2014) Sabrina Ceeraz et al.   ARTHRITIS RESEARCH & THERAPY

Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy

(2014) Bronwen R. Burton et al.   Nature Communications

Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

(2014) F. S. Hodi et al.   Cancer Immunology Research

Subverting the adaptive immune resistance mechanism to improve clinical responses to immune checkpoint blockade therapy

(2014) Young J Kim   OncoImmunology

Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy

(2013) Matthew D. Vesely et al.   Annals of the New York Academy of Sciences

Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

(2013) Christiane Meyer et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer

(2013) Kouichirou Aida et al.   CANCER SCIENCE

Adipokines in obesity

(2013) Viviane de Oliveira Leal et al.   CLINICA CHIMICA ACTA

Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs

(2013) B. Allard et al.   CLINICAL CANCER RESEARCH

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Macrophage biology in development, homeostasis and disease

(2013) Thomas A. Wynn et al.   NATURE

MHC Class II Antigen Presentation by Dendritic Cells Regulated through Endosomal Sorting

(2013) T. ten Broeke et al.   Cold Spring Harbor Perspectives in Biology

Mechanisms of Obesity-Induced Inflammation and Insulin Resistance: Insights into the Emerging Role of Nutritional Strategies

(2013) Maeve A. McArdle et al.   Frontiers in Endocrinology

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes

(2012) A. Calcinotto et al.   CANCER RESEARCH

BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

(2012) C. Liu et al.   CLINICAL CANCER RESEARCH

Modulation of GITR for cancer immunotherapy

(2012) David A Schaer et al.   CURRENT OPINION IN IMMUNOLOGY

Adiponectin: mechanistic insights and clinical implications

(2012) A. T. Turer et al.   DIABETOLOGIA

The TIGIT/CD226 Axis Regulates Human T Cell Function

(2012) E. Lozano et al.   JOURNAL OF IMMUNOLOGY

A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis and modulates key biomarkers in vivo

(2012) C Eberlein et al.   ONCOGENE

Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa

(2012) E. T. Clambey et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy

(2011) Oliver Kepp et al.   CANCER AND METASTASIS REVIEWS

The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy

(2011) T. Fu et al.   CANCER RESEARCH

CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1

(2011) J. Fourcade et al.   CANCER RESEARCH

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

(2011) Paul F. Robbins et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine

(2011) Jacalyn Rosenblatt et al.   JOURNAL OF IMMUNOTHERAPY

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Slow Down and Survive: Enigmatic Immunoregulation by BTLA and HVEM

(2010) Theresa L. Murphy et al.   Annual Review of Immunology

Control of Immunity by the TNFR-Related Molecule OX40 (CD134)

(2010) Michael Croft   Annual Review of Immunology

Macrophage Expression of Hypoxia-Inducible Factor-1  Suppresses T-Cell Function and Promotes Tumor Progression

(2010) A. L. Doedens et al.   CANCER RESEARCH

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

(2010) R. K. Shrimali et al.   CANCER RESEARCH

Peripheral blood gene expression of B7 and CD28 family members associated with tumor progression and microscopic lymphovascular invasion in colon cancer patients

(2010) Hyunji Lee et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation

(2010) Adam D. Cohen et al.   PLoS One

Radiation-induced cell death mechanisms

(2010) David Eriksson et al.   TUMOR BIOLOGY

Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody

(2009) M. Z. Dewan et al.   CLINICAL CANCER RESEARCH

A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC

(2009) Kent S. Boles et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation

(2009) Guifang Cai et al.   IMMUNOLOGICAL REVIEWS

Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling

(2009) Carsten Linnemann et al.   IMMUNOLOGY

Innate immunity

(2009) Stuart E. Turvey et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

(2009) Loise M. Francisco et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells

(2009) J. F. Grosso et al.   JOURNAL OF IMMUNOLOGY

Cutting Edge: OX40 Agonists Can Drive Regulatory T Cell Expansion if the Cytokine Milieu Is Right

(2009) C. E. Ruby et al.   JOURNAL OF IMMUNOLOGY

Unconventional ligand activation of herpesvirus entry mediator signals cell survival

(2009) T. C. Cheung et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity

(2009) N. Stanietsky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis

(2008) Li Yang et al.   CANCER CELL

TGFβ in Cancer

(2008) Joan Massagué   CELL

Endocytosis mechanisms and the cell biology of antigen presentation

(2008) Sven Burgdorf et al.   CURRENT OPINION IN IMMUNOLOGY

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

(2008) Xin Yu et al.   NATURE IMMUNOLOGY

Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis

(2007) Ping Zhang et al.   MOLECULAR IMMUNOLOGY